Home Cart Sign in  
Chemical Structure| 30418-59-8 Chemical Structure| 30418-59-8

Structure of 3-Aminophenylboronic acid
CAS No.: 30418-59-8

Chemical Structure| 30418-59-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Wen Ren ; Yuling Deng ; Jacob D. Ward ; Rebecca Vairin ; Ruoli Bai b ; Hashini I. Wanniarachchi , et al.

Abstract: The synthesis and evaluation of small-molecule inhibitors of tubulin polymerization remains a promising approach for the development of new therapeutic agents for cancer treatment. The natural products colchicine and combretastatin A-4 (CA4) inspired significant drug discovery campaigns targeting the colchicine site located on the beta-subunit of the tubulin heterodimer, but so far these efforts have not yielded an approved drug for cancer treatment in human patients. Interest in the colchicine site was enhanced by the discovery that a subset of colchicine site agents demonstrated dual functionality as both potent antiproliferative agents and effective vascular disrupting agents (VDAs). Our previous studies led to the discovery and development of a 2-aryl-3-aroyl-indole analogue (OXi8006) that inhibited tubulin polymerization and demonstrated low nM IC50 values against a variety of human cancer cell lines. A water-soluble phosphate prodrug salt (OXi8007), synthesized from OXi8006, displayed promising vascular disrupting activity in mouse models of cancer. To further extend structure-activity relationship correlations, a series of 6-aryl-3-aroyl-indole analogues was synthesized and evaluated for their inhibition of tubulin polymerization and cytotoxicity against human cancer cell lines. Several structurally diverse molecules in this small library were strong inhibitors of tubulin polymerization and of MCF-7 and MDA-MB-231 human breast cancer cells. One of the most promising analogues (KGP591) caused significant G2/M arrest of MDA-MB-231 cells, disrupted microtubule structure and cell morphology in MDA-MB-231 cells, and demonstrated significant inhibition of MDA-MB-231 cell migration in a wound healing (scratch) assay. A phosphate prodrug salt, KGP618, synthesized from its parent phenolic precursor, KGP591, demonstrated significant reduction in bioluminescence signal when evaluated in vivo against an orthotopic model of kidney cancer (RENCA-luc) in BALB/c mice, indicative of efficacy. The most active compounds from this series offer promise as anticancer therapeutic agents.

Keywords: Inhibitors of tubulin polymerization ; Vascular disrupting agents ; synthesis ; Molecular docking ; Antiproliferative agents ; Inhibitors of cell migration

Purchased from AmBeed: ; ; ; ; ; 64-86-8 ; ; ; ; ; ; ; ; 4521-61-3 ; 4521-61-3 ; 87199-18-6 ; 64-86-8 ; 64-86-8 ; 128796-39-4 ; 5720-05-8 ; 64-86-8

Alternative Products

Product Details of [ 30418-59-8 ]

CAS No. :30418-59-8
Formula : C6H8BNO2
M.W : 136.94
SMILES Code : OB(C1=CC=CC(N)=C1)O
MDL No. :MFCD00007755
InChI Key :JMZFEHDNIAQMNB-UHFFFAOYSA-N
Pubchem ID :92269

Safety of [ 30418-59-8 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P301+P312-P302+P352-P304+P340-P305+P351+P338

Computational Chemistry of [ 30418-59-8 ] Show Less

Physicochemical Properties

Num. heavy atoms 10
Num. arom. heavy atoms 6
Fraction Csp3 0.0
Num. rotatable bonds 1
Num. H-bond acceptors 2.0
Num. H-bond donors 3.0
Molar Refractivity 40.67
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

66.48 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.0
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.15
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

-1.04
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.36
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.44
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

-0.54

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.16
Solubility 9.44 mg/ml ; 0.0689 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.1
Solubility 10.8 mg/ml ; 0.0789 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.9
Solubility 17.3 mg/ml ; 0.126 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

Yes
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.03 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

2.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.61

Application In Synthesis of [ 30418-59-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 30418-59-8 ]

[ 30418-59-8 ] Synthesis Path-Downstream   1~8

  • 1
  • [ 4138-26-5 ]
  • [ 30418-59-8 ]
  • [ 90914-41-3 ]
  • piperidine-3-carboxylic acid [3-(3-amino-phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-yl]-amide [ No CAS ]
  • 2
  • [ 1112982-76-9 ]
  • [ 30418-59-8 ]
  • [ 1112980-79-6 ]
YieldReaction ConditionsOperation in experiment
78% With potassium carbonate;(1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; In 1,4-dioxane; water; at 90 - 99℃; for 4h; Step 2. N-(5-(3-aminophenyl)thiazolo[5.4-b1pyridin-2-yl)acetamide (Example 156); <strong>[1112982-76-9]N-(5-bromothiazolo[5,4-b]pyridin-2-yl)acetamide</strong> (1.504 g, 5.527 mmol), 3-aminophenylboronic acid monohydrate (1.316 g, 8.493 mmol), Pd(dppf)Cl2-DCM complex (604.4 mg, 0.7401 mmol), and potassium carbonate (2.292 g, 16.58 mmol) were suspended in 1,4-dioxane (45 ml) and water (15 ml) was added. Argon was bubbled through the solution for about 30 seconds, and then the flask was fit with a reflux condensor and placed in a preheated oil bath (90 - 99 C) and stirred under argon for 4 hours. The reaction was cooled to room temperature, filtered, and the solid was washed with DCM and MeOH. The filtrate was concentrated, treated with DCM and MeOH, and filtered. The solid was collected and set aside, and the filtrate was concentrated, treated with Et2O, and filtered. Solid washed with Et2O. This solid was combined with the first batch and dried under high vacuum first at room temperature, anphithen at ~ 50 C. This solid was treated with deionized water and filtered, and the solid was washed with water, collected, and dried under high vacuum in water bath (~ 50 C) to afford N-(5-(3- aminophenyl)thiazolo[5,4-b]pyridin-2-yl)acetamide (1.22 g, 78% yield). MS (ESI pos. ion) m/z: 285. Calculated exact mass for C14H]2N4OS 284.
  • 3
  • [ 51376-06-8 ]
  • [ 30418-59-8 ]
  • [ 1170691-48-1 ]
  • 4
  • [ 1111637-94-5 ]
  • [ 30418-59-8 ]
  • 3-(3-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)aniline [ No CAS ]
YieldReaction ConditionsOperation in experiment
With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; caesium carbonate; In acetonitrile; at 85℃;Inert atmosphere; Sealed tube; A solution of 19 (100 mg, 0.473 mmol) and 23 (62 mg, 0.4739 mmol) in acetonitrile (5 mL) was added cesium carbonate (310 mg, 0.946 mmol). The reaction was degassed and purged with nitrogen for 15 min. Pd(dppf)Cl2 (25.4 mg, 0.0218 mmol) was added and again degassed and purged with nitrogen for 15 min. The reaction was stirred overnight at 85 C., allowed to cool to rt, then diluted with DCM (25 mL) and filtered through Celite plug and concentrated to get the crude compound. The resulting oil was purified via silica gel chromatography using a gradient of 40% ethyl acetate:hexane to afford compound 24.
  • 5
  • [ 30418-59-8 ]
  • [ 175205-81-9 ]
  • 3-(4-(trifluoromethyl)pyridine-2-yl)aniline [ No CAS ]
YieldReaction ConditionsOperation in experiment
87.4% Inert atmosphere; A PT-TFP ligand was obtainedfrom the reaction of <strong>[175205-81-9]2-bromo-4-(trifluoromethyl)pyridine</strong> (1.82 g, 8.03 mmol) and(3-aminophenyl)boronic acid (1.00 g, 7.30 mmol) by Suzuki coupling. The abstraction and purification processes are the same as described above. Yield: 87.4percent (1.52 g); 1H NMR(CDCl3, 500 MHz): deltaH(ppm) 8.38(s, 1H), 8.06(s, 1H), 7.66(s, 1H), 7.47(s, 1H), 7.15(s,1H), 6.65(s, 1H), 6.27(d, 2H)
  • 6
  • [ 79-41-4 ]
  • [ 30418-59-8 ]
  • [ 48150-45-4 ]
  • 7
  • [ 30418-59-8 ]
  • [ 171663-13-1 ]
  • tert-butyl ((3'-amino-[1,1'-biphenyl]-3-yl)methyl)carbamate [ No CAS ]
  • 8
  • [ 56442-17-2 ]
  • [ 30418-59-8 ]
  • (3-((4-((4-Fluorobenzyl)oxy)benzyl)amino)phenyl)boronic Acid [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 30418-59-8 ]

Organoborons

Chemical Structure| 206658-89-1

A186407 [206658-89-1]

3-Aminophenylboronic acid monohydrate

Similarity: 1.00

Chemical Structure| 85006-23-1

A108286 [85006-23-1]

(3-Aminophenyl)boronic acid hydrochloride

Similarity: 0.98

Chemical Structure| 80460-73-7

A201777 [80460-73-7]

(4-Aminophenyl)boronic acid hydrochloride

Similarity: 0.95

Chemical Structure| 5570-18-3

A100028 [5570-18-3]

(2-Aminophenyl)boronic acid

Similarity: 0.89

Chemical Structure| 178752-79-9

A359175 [178752-79-9]

3-(N,N-Dimethylamino)phenylboronic acid

Similarity: 0.87

Aryls

Chemical Structure| 206658-89-1

A186407 [206658-89-1]

3-Aminophenylboronic acid monohydrate

Similarity: 1.00

Chemical Structure| 85006-23-1

A108286 [85006-23-1]

(3-Aminophenyl)boronic acid hydrochloride

Similarity: 0.98

Chemical Structure| 80460-73-7

A201777 [80460-73-7]

(4-Aminophenyl)boronic acid hydrochloride

Similarity: 0.95

Chemical Structure| 5570-18-3

A100028 [5570-18-3]

(2-Aminophenyl)boronic acid

Similarity: 0.89

Chemical Structure| 178752-79-9

A359175 [178752-79-9]

3-(N,N-Dimethylamino)phenylboronic acid

Similarity: 0.87

Amines

Chemical Structure| 206658-89-1

A186407 [206658-89-1]

3-Aminophenylboronic acid monohydrate

Similarity: 1.00

Chemical Structure| 85006-23-1

A108286 [85006-23-1]

(3-Aminophenyl)boronic acid hydrochloride

Similarity: 0.98

Chemical Structure| 80460-73-7

A201777 [80460-73-7]

(4-Aminophenyl)boronic acid hydrochloride

Similarity: 0.95

Chemical Structure| 5570-18-3

A100028 [5570-18-3]

(2-Aminophenyl)boronic acid

Similarity: 0.89

Chemical Structure| 178752-79-9

A359175 [178752-79-9]

3-(N,N-Dimethylamino)phenylboronic acid

Similarity: 0.87